USA Tariff Shift Creates Breakthrough Opportunity for Pakistan’s Pharma Industry

KARACHI: Pakistan’s pharmaceutical sector is poised for a major export boom following a strategic shift in U.S. tariff policy. With Pakistani medicines now facing a 19% tariff—significantly lower than 25–50% for India and up to 50% for China—the country gains a rare competitive edge in accessing the lucrative U.S. healthcare market.

Why This Matters

The U.S. is currently grappling with medicine shortages, and Pakistan’s lower tariff rate positions it as a viable alternative supplier. However, success hinges on securing U.S. FDA approvals and meeting international quality benchmarks.

Expert Insights

Healthcare advisor Shahzad Haider emphasized the need for a strategic roadmap, including long-term supply agreements and investment in modern manufacturing facilities. He believes Pakistan could double its pharma exports within two years if compliance and capacity challenges are addressed.

Industry Voices

Former PPMA Chairman Dr. Kaiser Waheed noted that while Pakistan already exports herbal medicines to the U.S., volumes are low. He sees untapped potential for broader pharmaceutical offerings, especially those recognized by global drug authorities.

Record-Breaking Growth

According to the Pakistan Bureau of Statistics, pharma exports surged 34% year-on-year, reaching $457 million in FY2024–25—the highest growth in over two decades. Pakistan now exports to over 70 countries, including the U.S., Europe, Central Asia, and Africa.